Choline C-11: Pulling Back the Curtain on Prostate Cancer - Mayo Clinic
About 90,000 men annually seek treatment for recurrent prostate cancer, according to the Surveillance, Epidemiology and End Results database. Recurrent prostate cancer is defined as cancer that has recurred following initial therapy, which could include surgery, radiation therapy, hormone therapy or chemotherapy. Choline C-11 Injection has a short shelf life and must be made in a specialized facility and given to patients within minutes after production. Mayo Clinic has the integrated production, imaging and pathology facilities to provide the benefit of Choline C-11 PET imaging to patients. Learn more updates for medical professionals on Mayo Clinic's Medical Professional Resource Center: https://mayocl.in/2OjHX7a
To refer a patient to Mayo Clinic, visit: https://mayocl.in/2QQISPb
